Edwards Lifesciences posts PROGRESS trial baseline data on moderate aortic stenosis patients at New York Valves 2026

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation

EW

0.00
  • Edwards Lifesciences released new clinical data at New York Valves 2026; fuller PROGRESS trial results are slated for presentation at TCT later this year.
  • PROGRESS baseline data indicate many moderate aortic stenosis patients carry risk features, supporting a rationale to test earlier TAVR use.
  • Seven-year PARTNER 3 durability results for the SAPIEN 3 platform were presented and published, reinforcing long-term performance in a key franchise.
  • New EARLY TAVR findings were also presented, adding support for earlier intervention strategies in aortic valve disease management.
  • Registry and trial updates in mitral disease pointed to sustained safety and effectiveness for PASCAL, supporting continued expansion in structural heart.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edwards Lifesciences Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260626921634) on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.